This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

George A. Williams, MD; Fred H. Lambrou, MD; Glenn A. Jaffe, MD; Robert W. Snyder, MD, PhD; George D. J. Green, PhD; Robert G. Devenyi, MD, FRCSC; Gary W. Abrams, MD

Arch Ophthalmol. 1988;106(8):1055-1058.

Abstract
• Twenty-five micrograms of human recombinant tissue plasminogen activator (tPA) was injected intracamerally into the eyes of three aphakic patients who developed severe intraocular fibrin formation within 24 hours after vitrectomy surgery. Fluid obtained from gas-fluid exchange specimens taken 24 hours after tPA injection was analyzed for tPA by an enzymelinked immunosorbent assay and a spectrophotometric solid-phase fibrin assay. In each of the three patients, complete fibrin resolution occurred within four hours after the tPA injection. There were no complications associated with the intraocular tPA injections. There was measurable tPA activity 24 hours after the initial injection ranging from 0.23 to 1.4 µg. In contrast, tPA was undetectable in gas-fluid exchange specimens obtained from seven patients who did not receive intraocular tPA injections. Intraocular tPA is an effective means of treating postvitrectomy fibrin formation in selected aphakic patients.

Author Affiliations
From the Department of Ophthalmology, Medical College of Wisconsin, Milwaukee (Drs Williams, Lambrou, Jaffe, Snyder, Devenyi, and Abrams); and Invitron Corp, St Louis (Dr Green).

Footnotes
Accepted for publication April 22,1988.

Reprint requests to Eye Institute, Medical College of Wisconsin, 8700 W Wisconsin Ave, Milwaukee, WI 53226 (Dr Williams).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Tissue plasminogen activator therapy for the eye
Tripathi and Tripathi
Br J Ophthalmol 2005;89:1390-1391.
FULL TEXT  

Argatroban Inhibits Intraocular Fibrin Formation After Vitrectomy in Rabbits
Maeno et al.
Arch Ophthalmol 2000;118:1401-1405.
ABSTRACT | FULL TEXT  

Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study
Heiligenhaus et al.
Br J Ophthalmol 1998;82:810-815.
ABSTRACT | FULL TEXT  

Tissue Plasminogen Activator and Staphylococcus epidermidis Endophthalmitis
Ryan and Mizener
Arch Ophthalmol 1993;111:1117-1122.
ABSTRACT  

Evaluation of a Commercial Recombinant Tissue-Type Plasminogen Activator Preparation in the Subretinal Space of the Cat
Benner et al.
Arch Ophthalmol 1991;109:1731-1736.
ABSTRACT  

Intraocular Penetration of Topical Tissue Plasminogen Activator
Lim et al.
Arch Ophthalmol 1991;109:714-717.
ABSTRACT  

Retinal Toxicity of Human Tissue Plasminogen Activator in Vitrectomized Rabbit Eyes
Irvine et al.
Arch Ophthalmol 1991;109:718-722.
ABSTRACT  

Inhibition of Intraocular Fibrin Formation Following Infusion of Low-Molecular-Weight Heparin During Vitrectomy
Iverson et al.
Arch Ophthalmol 1991;109:405-409.
ABSTRACT  

Antitransferrin Receptor Immunotoxin Inhibits Proliferating Human Retinal Pigment Epithelial Cells
Jaffe et al.
Arch Ophthalmol 1990;108:1163-1168.
ABSTRACT  

The Effect of Tissue Plasminogen Activator on Retinal Bleeding
Sternberg et al.
Arch Ophthalmol 1990;108:720-722.
ABSTRACT  

Retinal Toxicity of Recombinant Tissue Plasminogen Activator in the Rabbit
Johnson et al.
Arch Ophthalmol 1990;108:259-263.
ABSTRACT  

Rebleeding in Experimental Traumatic Hyphema Treated With Intraocular Tissue Plasminogen Activator
Williams et al.
Arch Ophthalmol 1990;108:264-266.
ABSTRACT